Aquestive Therapeutics Files 8-K
Ticker: AQST · Form: 8-K · Filed: Oct 25, 2024 · CIK: 1398733
| Field | Detail |
|---|---|
| Company | Aquestive Therapeutics, Inc. (AQST) |
| Form Type | 8-K |
| Filed Date | Oct 25, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, filing, financials
Related Tickers: AQST
TL;DR
AQST filed an 8-K, likely with financial updates. Keep an eye out.
AI Summary
Aquestive Therapeutics, Inc. filed an 8-K on October 25, 2024, reporting on other events and financial statements. The company, incorporated in Delaware with its principal executive offices in Warren, NJ, previously operated under the name MonoSol Rx, Inc. before changing its name on May 7, 2007. The filing does not detail specific events or financial figures but serves as a notification of these items.
Why It Matters
This filing indicates Aquestive Therapeutics is providing updates to the SEC, which could include material information relevant to investors.
Risk Assessment
Risk Level: low — The filing is a standard 8-K notification and does not contain specific negative or positive news that would inherently increase risk.
Key Players & Entities
- Aquestive Therapeutics, Inc. (company) — Registrant
- MonoSol Rx, Inc. (company) — Former company name
- October 25, 2024 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- Warren, NJ (location) — Principal executive offices
FAQ
What specific events are being reported in this 8-K filing?
The filing indicates 'Other Events' and 'Financial Statements and Exhibits' are being reported, but the specific details of these events are not provided in the header information.
When was Aquestive Therapeutics, Inc. incorporated?
Aquestive Therapeutics, Inc. was incorporated in Delaware.
What was the previous name of Aquestive Therapeutics, Inc.?
The previous name of Aquestive Therapeutics, Inc. was MonoSol Rx, Inc.
On what date did the company change its name from MonoSol Rx, Inc.?
The company changed its name from MonoSol Rx, Inc. on May 7, 2007.
Where are Aquestive Therapeutics, Inc.'s principal executive offices located?
Aquestive Therapeutics, Inc.'s principal executive offices are located at 30 Technology Drive, Warren, NJ 07059.
Filing Stats: 549 words · 2 min read · ~2 pages · Grade level 11.7 · Accepted 2024-10-25 08:05:43
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share AQST Nasdaq Global Market I
Filing Documents
- aqst-20241025.htm (8-K) — 29KB
- aquestivetherapeutics-ac.htm (EX-99.1) — 14KB
- acaai_abstracts-final.htm (EX-99.2) — 3KB
- acaai2024poster-final.htm (EX-99.3) — 7KB
- acaai2024poster-final001.jpg (GRAPHIC) — 190KB
- acaai_abstracts-final001.jpg (GRAPHIC) — 187KB
- aquestivetherapeutics-ac001.jpg (GRAPHIC) — 259KB
- aquestivetherapeutics-ac002.jpg (GRAPHIC) — 266KB
- aquestivetherapeutics-ac003.jpg (GRAPHIC) — 326KB
- aquestivetherapeutics-ac004.jpg (GRAPHIC) — 43KB
- 0001628280-24-043761.txt ( ) — 1937KB
- aqst-20241025.xsd (EX-101.SCH) — 2KB
- aqst-20241025_lab.xml (EX-101.LAB) — 21KB
- aqst-20241025_pre.xml (EX-101.PRE) — 12KB
- aqst-20241025_htm.xml (XML) — 3KB
01
Item 8.01 Other Events. On October 25, 2024, Aquestive Therapeutics, Inc. (the "Company") issued a press release announcing a subsequent analysis of the data from the pivotal study of its product candidate Anaphylm (epinephrine) Sublingual Film demonstrating comparable PK and PD data regardless of variable placement or intraoral movement will be presented at the American College of Allergy Asthma and Immunology (ACAAI) annual meeting, which is being held from October 24-28 in Boston, Massachusetts. The press release is filed as Exhibit 99.1 hereto and incorporated herein by reference. On October 25, 2024, the Company presented an abstract and poster titled "Sublingual Epinephrine Film's Mucoadhesive Properties Ensures Consistent Oral Placement and Drug Release" at the ACAAI annual meeting. A copy of the abstract is filed as Exhibit 99.2 and a copy of the poster is filed as Exhibit 99.3 hereto and are incorporated herein by reference.
Financial Statements and Exhibits
Financial Statements and Exhibits (d) Exhibits. Exhibit Number Description 99.1 Press Release, dated October 25, 2024. 99.2 Sublingual Epinephrine Film's Mucoadhesive Properties Ensures Consistent Oral Placement and Drug Release Abstract 99.3 Sublingual Epinephrine Film's Mucoadhesive Properties Ensures Consistent Oral Placement and Drug Release Poster SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: October 25, 2024 Aquestive Therapeutics, Inc. By: /s/ A. Ernest Toth, Jr Name: A. Ernest Toth, Jr. Title: Chief Financial Officer